Moleculin to Present at 38th Annual ROTH Conference
Rhea-AI Summary
Moleculin (Nasdaq: MBRX) will present at the 38th Annual ROTH Conference in Dana Point, CA, participating in a fireside chat on March 24, 2026, 12:00–12:25 PM PT.
Presenters include Walter Klemp, Founder, President, Chairman & CEO, and Jon Foster, EVP & CFO. Investors may register or arrange one-on-one meetings through ROTH.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – MBRX
On the day this news was published, MBRX gained 5.37%, reflecting a notable positive market reaction. Argus tracked a trough of -4.8% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $548K to the company's valuation, bringing the market cap to $10.76M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 11 | CEO Corner update | Positive | +3.0% | CEO discussed MIRACLE Phase 3 progress and upcoming interim unblinding. |
| Feb 19 | Warrant exercise financing | Negative | -44.3% | Immediate warrant exercises for cash and issuance of new warrants drove dilution concerns. |
| Feb 18 | Clinical data update | Positive | +5.5% | Reported 40% blinded CRc in MIRACLE trial with continued absence of cardiotoxicity. |
| Feb 17 | Patent allowance | Positive | +5.1% | Japan patent allowance for liposomal Annamycin reconstitution methods strengthened IP. |
| Feb 13 | Investor outreach initiative | Positive | +2.9% | Launch of CEO Corner platform to communicate strategy and clinical progress. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has generally seen price moves aligned with the nature of the event, with positive clinical/patent updates lifting shares and financing-related warrants triggering a sharp selloff.
Over the past month, MBRX highlighted MIRACLE trial progress, including a 40% CRc rate and plans for unblinding after 45 patients, alongside confirmation of no cardiotoxicity in 90 subjects. A Japanese patent allowance further strengthened Annamycin IP, and the CEO Corner platform expanded investor communications. In contrast, a warrant exercise for about $8.3 million gross proceeds led to a steep decline, reflecting sensitivity to dilution versus operational milestones.
AI-generated analysis. How Rhea-AI works. Not financial advice.
– Management to participate in fireside chat presentation with Jonathan Aschoff, Senior Research Analyst at ROTH Capital Partners
HOUSTON, March 17, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that it will participate in a fireside chat at the 38th Annual ROTH Conference being held March 22-24, 2026 in Dana Point, CA.
Details of the fireside chat presentation are as follows:
Date and Time: Tuesday, March 24, 2026 at 12:00-12:25 PM PT
Location: BROWN - HEALTHCARE - VIRTUAL (SUITE 1051)
Presenters: Walter Klemp, Founder, President, Chairman & CEO; Jon Foster, EVP & CFO
Registration Link: Here
Investors interested in arranging one-on-one meetings should contact their ROTH representative. For more information, please visit the conference website here.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company’s lead program, Annamycin (also known as naxtarubicin), is a next-generation highly efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.
The Company has begun the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC (the combination of Annamycin and cytarabine, also referred to as “Ara-C”) and, for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.
Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin also has in its pipeline a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications.
For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
MBRX@jtcir.com
